Core Viewpoint - Nanjing Pharmaceutical Co., Ltd. is issuing convertible bonds to unspecified investors, with a total amount of RMB 1,081,491,000, to be used for various investment projects [3][16][18]. Group 1: Issuance Details - The company has received approval from its board and regulatory authorities for the issuance of 10,814,910 convertible bonds, each with a face value of RMB 100 [3][4]. - The net proceeds from the issuance amount to RMB 1,069,040,922.31, which has been verified by KPMG Huazhen [3][18]. - The bonds will have a maturity period of six years from the issuance date, with an annual interest rate starting at 0.20% in the first year [5][12]. Group 2: Bond Terms - The initial conversion price for the bonds is set at RMB 5.29 per share, subject to adjustments based on corporate actions such as stock dividends and capital increases [8][21]. - The company has the right to redeem the bonds at 108% of the face value after five trading days post-maturity if certain conditions are met [9][10]. - Holders of the bonds can sell them back to the company at face value plus accrued interest if the stock price falls below 70% of the conversion price during the last two interest years [10][11]. Group 3: Use of Proceeds - The total investment amount for the projects funded by the bond proceeds is RMB 118,665,520, with the shortfall to be covered by the company’s own funds [16][18]. - The company plans to allocate the raised funds to specific projects, ensuring that the actual net proceeds are utilized effectively [16][18]. Group 4: Shareholder Rights - Original shareholders will have priority in subscribing to the bonds based on their holdings as of the record date, with specific timelines for subscription and payment [14][16]. - The company will ensure that the rights of bondholders are protected and that any adjustments to the conversion price are communicated transparently [20][22].

债券代码：110098 债券简称：南药转债 证券代码：600713 证券简称：南京医药 编号：ls2025-091 南京医药股份有限公司 关于因实施权益分派调整可转债转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 调整前转股价格：5.29 元/股 ? 调整后转股价格：5.12 元/股 ? "南药转债"本次转股价格调整实施日期：2025 年 6 月 30 日 限公司向不特定对象发行可转换公司债券注册的批复》（证监许可【2024】1736 号）， 核准南京医药股份有限公司（以下简称"公司"）本次可转换公司债券（以下简称"可 转债"）发行。公司向不特定对象发行可转债 10,814,910 张，每张面值为人民币 100 元，并于 2025 年 1 月 20 日在上海证券交易所上市交易（债券简称：南药转债，债券 代码：110098），初始转股价格为 5.29 元/股。 一、转股价格调整依据 公司股份回购专用证券账户持有股数）为基数分配利润，向全体股东每 10 股派发现金 红利 1.70 元（含税）。在 ...

中国医药（600056）公告，公司收到参股公司重庆医健股东重庆渝富拟公开挂牌转让重庆医健24%股权 的通知，股权转让底价为22.06亿元。公司决定放弃该股权的优先购买权。本次放弃优先购买权事项尚 无法确定是否构成关联交易，不构成重大资产重组情形。公司第九届董事会第28次会议审议通过该议 案，尚需提交股东大会审议。本次放弃优先购买权不会导致公司合并报表范围发生变化，亦不会导致公 司对重庆医健的持股比例下降，不存在损害公司及股东利益的情形，不会对公司财务及经营状况产生重 大影响。 ...

北京市竞天公诚律师事务所上海分所 关于 南京医药股份有限公司 差异化分红 法律意见书 上海市徐汇区淮海中路 1010 号嘉华中心 45 层 邮编：200031 Suite 45/F, K.Wah Centre, 1010 Huaihai Road (M), Xuhui District, Shanghai 200031, China 电话/Tel: +86 21 5404 9930 传真/Fax: +86 21 5404 9931 网址/Website: http://www.jingtian.com 二〇二五年六月 北京市竞天公诚律师事务所上海分所 法律意见书 北京市竞天公诚律师事务所上海分所 关于南京医药股份有限公司 差异化分红之法律意见书 致：南京医药股份有限公司 根据《中华人民共和国公司法》 （以下简称"《公司法》"）、 《中华人民共和国 证券法》 （以下简称"《证券法》"）、 《上市公司股份回购规则》 （以下简称"《回购 师事务所从事证券法律业务管理办法》和《律师事务所证券法律业务执业规则（试 行）》等规定以及在本法律意见书出具日之前已经发生或存在的事实出具法律意 见。本所已经严格履行了法定职责，遵 ...

通过了《关于以集中竞价交易方式回购公司股份方案的议案》，同意公司以自有 资金或自筹资金通过集中竞价交易方式回购公司股份，用于实施 2025 年限制性 股票激励计划。截至 2025 年 4 月 30 日，公司通过集中竞价交易方式已累计回购 公司股份 16,299,951 股。 议审议通过了《关于向公司 2025 年限制性股票激励计划激励对象首次授予限制 性股票的议案》，同意公司向 173 名激励对象首次授予 16,059,000 股限制性股票。 在资金缴纳过程中，有 1 名激励对象放弃认购，涉及股数 40,000 股，因此本次 激励计划首次授予激励对象人数由 173 人调整为 172 人，首次授予股数由 性股票激励计划首次授予登记工作。本次授予完成后，公司回购专用证券账户 （B887180567）中剩余 280,951 股无限售流通股。 根据《公司法》《证券法》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关法律、法规及规范性文件的规定，公司回购专用账户持 有的公司股份不参与利润分配。因此，公司 2024 年度权益分配实施差异化分红。 二、股东大会审议通过的差异化权益分派方案 中信建投证券股份 ...

Core Viewpoint - The company has adjusted its 2024 annual profit distribution cash dividend total from CNY 222,585,426.80 to CNY 222,468,028.71 due to changes in total share capital resulting from the repurchase and cancellation of restricted stock options [1][2] Summary by Sections Adjustment of Profit Distribution - The cash dividend per share remains unchanged at CNY 0.17 (including tax) despite the total amount being adjusted [1] - The adjustment was necessary because the company repurchased and canceled 409,626 shares of restricted stock, affecting the total share capital [2] Pre-Adjustment Profit Distribution Plan - The initial profit distribution plan was based on a total share capital of 1,309,326,040 shares, with a proposed cash dividend of CNY 1.70 per 10 shares [1] - The total profit allocated for distribution was CNY 222,585,426.80, which exceeded 10% of the distributable profit and 30% of the net profit attributable to shareholders [1] Post-Adjustment Profit Distribution Plan - After the cancellation of shares, the total share capital decreased to 1,308,916,414 shares, leading to a new distribution base of 1,308,635,463 shares [4] - The adjusted total profit for distribution is now CNY 222,468,028.71, maintaining the cash dividend of CNY 1.70 per 10 shares [4] - The remaining distributable profit will be carried over to the next fiscal year [4]

证券代码：600713 证券简称：南京医药 公告编号：ls2025-088 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 每股分配比例 A 股每股现金红利0.17元 ? 相关日期 | | | | | 现金红利发放 | | --- | --- | --- | --- | --- | | 股份类别 | 股权登记日 | | 最后交易日 | 除权（息）日 | | | | | | 日 | | Ａ股 | 2025/6/27 | － | 2025/6/30 | 2025/6/30 | ? 差异化分红送转： 是 （2）本次差异化分红除权（息）参考价格 根据上海证券交易所的相关规定，公司按照以下公式计算除权（息）开盘参 考价： 除权（息）参考价格=（前收盘价格-现金红利）÷（1+流通股份变动比例） 一、通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 6 月 5 日召开的2024年年度股东大会审议通 过。 二、分配方案 截至股权登记日下午 ...

Core Viewpoint - The China General Technology (Group) Holding Co., Ltd. has implemented a warning education campaign to address issues identified in cases of misconduct, aiming to enhance accountability and rectify shortcomings within the organization [1][2][4] Group 1: Warning Education Implementation - The campaign involved over 11,000 party members receiving warning education through the analysis of typical cases [1] - Five typical cases of misconduct were selected for in-depth analysis, accompanied by the production of five educational videos featuring confessions from violators and insights from investigators [1][2] - The goal is to create a closed-loop warning education system that emphasizes self-examination and rectification based on identified issues [2] Group 2: Case Analysis and Recommendations - The China Medical Health Industry Co., Ltd. held a seminar focusing on identifying integrity risks across various business sectors, resulting in a list of issues and corrective measures [3] - The company proposed 16 corrective suggestions in response to a serious misconduct case, aiming to establish comprehensive supervision mechanisms for financial operations [3] Group 3: Future Directions - The organization plans to consolidate and deepen the results of the warning education, ensuring thorough investigation and rectification of issues to drive high-quality development [4]

Core Viewpoint - The legal opinion letter confirms the legality and validity of the procedures, qualifications, proposals, and voting results of the 2024 annual general meeting of Shanghai First Pharmaceutical Co., Ltd. [1][5] Group 1: Meeting Organization - The 2024 annual general meeting is scheduled for June 20, 2025, at the third meeting room on the 20th floor of 681 Xiaomuqiao Road, Xuhui District, Shanghai [1][2] - The meeting was announced on May 31, 2025, on the Shanghai Stock Exchange website, detailing the time, location, agenda, attendees, registration methods, and voting procedures [2][3] Group 2: Meeting Attendance - A total of 2 shareholders and their representatives attended the meeting, holding 100,278,034 shares with voting rights, which represents a significant portion of the total voting shares [3][4] - Additionally, 116 shareholders participated through the online voting system during the designated trading hours on June 20, 2025 [4] Group 3: Meeting Proposals - The meeting included several key proposals such as the 2024 Board of Directors' work report, 2024 Supervisory Board's work report, financial reports, profit distribution plan, and various resolutions regarding board member elections and compensation [4][5] - Proposals related to the financial service agreement with Bailian Group and the cancellation of the Supervisory Board were also discussed [4] Group 4: Voting Procedures and Results - The voting results indicated that proposals requiring a two-thirds majority were approved, while others needed a simple majority, with specific votes counted separately for minority investors [5] - The legal opinion confirms that all voting procedures and results comply with relevant laws and regulations, ensuring the legitimacy of the meeting outcomes [5]

Group 1 - The company will hold its first extraordinary general meeting of shareholders in 2025 on July 7 at 9:30 AM in Beijing [1][3] - The voting will be conducted through a combination of on-site and online voting systems provided by the Shanghai Stock Exchange [3][4] - The registration for attending the meeting will be open from June 30 to July 2, 2025, and shareholders must present identification and relevant documents [6][5] Group 2 - The meeting will review proposals that have already been approved by the company's board of directors [2][3] - Shareholders can vote through the Shanghai Stock Exchange's online voting system, with specific time slots for voting on the day of the meeting [1][4] - Shareholders holding multiple accounts can aggregate their voting rights across all accounts for the same category of shares [5][4]